Bruno Vergès
Service Endocrinologie
Diabétologie et Maladies Métaboliques
Hôpital du Bocage
CHU, 21000 Dijon
France
Name/email consistency: high
- Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein b100 catabolism in type 2 diabetes mellitus. Vergès, B., Guiu, B., Cercueil, J.P., Duvillard, L., Robin, I., Buffier, P., Bouillet, B., Aho, S., Brindisi, M.C., Petit, J.M. Arterioscler. Thromb. Vasc. Biol. (2012)
- Strategies for insulin initiation: insights from the French LIGHT observational study. Vergès, B., Brun, J.M., Tawil, C., Alexandre, B., Kerlan, V. Diabetes Metab. Res. Rev. (2012)
- Combination lipid therapy in type 2 diabetes mellitus. Vergès, B. Expert. Opin. Pharmacother (2011)
- Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Vergès, B. Atherosclerosis (2010)
- Lipid modification in type 2 diabetes: the role of LDL and HDL. Vergès, B. Fundam. Clin. Pharmacol (2009)
- Lipid disorders in type 1 diabetes. Vergès, B. Diabetes Metab. (2009)
- Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. Vergès, B., Florentin, E., Baillot-Rudoni, S., Petit, J.M., Brindisi, M.C., Pais de Barros, J.P., Lagrost, L., Gambert, P., Duvillard, L. J. Lipid Res. (2009)
- Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. Vergès, B., Florentin, E., Baillot-Rudoni, S., Monier, S., Petit, J.M., Rageot, D., Gambert, P., Duvillard, L. Diabetologia (2008)
- Plasma N-terminal Pro-Brain Natriuretic Peptide (Nt-proBNP) level and prognosis after myocardial infarction in diabetes. Vergès, B., Zeller, M., Beer, J.C., Cottin, Y. Diabetes Metab. (2008)
- Impact of fasting glycemia on short-term prognosis after acute myocardial infarction. Vergès, B., Zeller, M., Dentan, G., Beer, J.C., Laurent, Y., Janin-Manificat, L., Makki, H., Wolf, J.E., Cottin, Y. J. Clin. Endocrinol. Metab. (2007)
- Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels. Vergès, B. Fundam. Clin. Pharmacol (2007)
- Adiponectin is an important determinant of apoA-I catabolism. Vergès, B., Petit, J.M., Duvillard, L., Dautin, G., Florentin, E., Galland, F., Gambert, P. Arterioscler. Thromb. Vasc. Biol. (2006)
- Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Vergès, B. Curr. Opin. Lipidol. (2006)
- Diabetic dyslipidaemia: insights for optimizing patient management. Vergès, B. Curr. Med. Res. Opin (2005)
- High plasma N-terminal pro-brain natriuretic peptide level found in diabetic patients after myocardial infarction is associated with an increased risk of in-hospital mortality and cardiogenic shock. Vergès, B., Zeller, M., Desgrès, J., Dentan, G., Laurent, Y., Janin-Manificat, L., L'Huillier, I., Rioufol, G., Beer, J.C., Makki, H., Rochette, L., Gambert, P., Cottin, Y. Eur. Heart J. (2005)
- Role for fibrate therapy in diabetes: evidence before FIELD. Vergès, B. Curr. Opin. Lipidol. (2005)
- New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Vergès, B. Diabetes Metab. (2005)
- Clinical interest of PPARs ligands. Vergès, B. Diabetes Metab. (2004)
- Effects of cardiac rehabilitation on exercise capacity in Type 2 diabetic patients with coronary artery disease. Vergès, B., Patois-Vergès, B., Cohen, M., Lucas, B., Galland-Jos, C., Casillas, J.M. Diabet. Med. (2004)
- Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Vergès, B., Boureille, F., Goudet, P., Murat, A., Beckers, A., Sassolas, G., Cougard, P., Chambe, B., Montvernay, C., Calender, A. J. Clin. Endocrinol. Metab. (2002)
- The impact of prandial glucose regulation in practice. Vergès, B. Diabetes Nutr. Metab. (2002)
- Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. Vergès, B., Guerci, B., Durlach, V., Galland-Jos, C., Paul, J.L., Lagrost, L., Gambert, P. J. Lipid Res. (2001)